MedTrace Logo

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

NCT01853306 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2017-11-21

No results posted yet for this study

Summary

This is a 3 part phase 1 study to evaluate the safety, pharmacokinetic and oral bioavailability of veliparib in subjects with solid tumors.

Conditions

  • Oncology
  • BRCA Mutated
  • High Grade Serous Ovarian Cancer
  • BRCA Mutated Breast Cancer

Interventions

DRUG

Veliparib

veliparib

Sponsors & Collaborators

Principal Investigators

  • Philip Komarnitsky, MD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-18
Primary Completion
2017-05-03
Completion
2017-06-29

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01853306 on ClinicalTrials.gov